PEG Uricase Long Acting Agent for Treating Gout
Pegloticase co-administered with high MW polyethylene glycol effectively reduces PEG-immunogenicity and restores prolonged circulation in mouse - ScienceDirect
Anti-PEG Abs in the clinic 2 . 1 The case of PEG-uricase | Semantic Scholar
Plasma uricase activity and plasma uric acid concentrat | Open-i
File:PegUricase.png - Wikipedia
Emerging Strategies for Effective Management of Treatment-Failure Gout (Slides with Transcript)
![PDF] A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/41089ef858e1e35042f1b1ad8aa3023686e05919/14-Figure9-1.png "PDF] A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties | Semantic Scholar")
PDF] A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties | Semantic Scholar
Immunogenicity of unmodified uricase and PEG-uricases. The development... | Download Scientific Diagram
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout | Arthritis Research & Therapy | Full Text
Enhancing the Response Rate to Recombinant Uricases in Patients with Gout | BioDrugs
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase | Arthritis Research & Therapy
A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties
WO2003011211A2 - Peg-modified uricase - Google Patents
Anti-PEG Abs in the clinic 2 . 1 The case of PEG-uricase | Semantic Scholar
Time course of appearance of IgM and IgG antibodies aga | Open-i
Engineering polynorbornene based uricase conjugates for gout therapy - American Chemical Society
Uricase Therapy of Gout | Musculoskeletal Key
Effect of treatment with PEG-uricase on uric acid excretion. Ten... | Download Scientific Diagram
Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia | Nature Communications
Biochemical and biopharmaceutical properties of PEGylated uricase - ScienceDirect
Zwitterionic Nanocages Overcome the Efficacy Loss of Biologic Drugs | UW Bioengineering
PEG antibodies do not cross‐react with uricase‐POEGMA. The reactivity... | Download Scientific Diagram
